|Bid||0.00 x 2900|
|Ask||0.00 x 800|
|Day's Range||92.11 - 95.80|
|52 Week Range||66.93 - 101.73|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||10.69|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.56|
Richard Pzena (Trades, Portfolio), t he founder and co-chief investment officer of Pzena Investment Management, sold shares of the following stocks during the fourth quarter. Warning! GuruFocus has detected 2 Warning Sign with QSR. The guru closed his Express Scripts Holding Co. (ESRX) stake.
Cigna Corp. said a new federal proposal that would curb rebates from drugmakers would have minimal impact on its results and offered conservative earnings guidance for 2019, the first year it will include the operations of Express Scripts Holding Co. Cigna said that for 2019, it projects adjusted income of $6.2 billion to $6.4 billion, or $16 to $16.50 per share. Analysts wrote that this range was slightly lower than consensus projections, but it included about $200 million, or 40 cents a share, in lingering overhead costs tied to Anthem Inc.’s early exit from its pharmacy-benefit contract with Express Scripts.
The U.S. government's proposal to eliminate rebates that pharmacy benefit managers receive from drugmakers will not have a meaningful impact on growth, and does not affect the commercial market, Cigna Corp Chief Executive Officer David Cordani said on Friday. Investors are worried that Cigna, which closed its $52 billion acquisition of PBM Express Scripts in December, could be hurt by the Trump administration's proposal targeting after-market discounts that middlemen in the pharmaceutical supply chain have received for decades.
Anthem stock vaulted higher, touching a buy point intraday, after the company issued a far-better-than-expected profit forecast this year.
Corp.’s recent acquisition of Express Scripts Holding Co., Anthem’s previous pharmacy-benefit manager, which allowed Anthem to terminate their contract well before the end of 2019, when the break had been expected. Anthem said it will exit the Express Scripts contract on March 1 and begin a yearlong process of transition the next day, with members beginning to migrate in the second quarter. Analysts wrote that the adjusted earnings projection handily beat consensus estimates of around $17.61, with the projected results boosted by several factors including expected membership growth, including in the Medicare Advantage program.
This concludes a rating review initiated on March 9, 2018 following the announcement that Cigna Corporation ("Cigna") reached a definitive agreement to acquire Express Scripts in a transaction valued at approximately $67 billion. Moody's changed the direction of the rating review from uncertain to downgrade on September 6, 2018.
Cigna Holding Co (NYSE: CI) recently completed its acquisition of pharmacy benefit manager Express Scripts. Raymond James analyst John Ransom upgraded Cigna from Market Perform to Outperform with a $215 price target. Wells Fargo Securities analyst Peter Costa maintained a Market Perform rating for Cigna and lowered the price target from $221 to $200.
Express Scripts CEO Tim Wentworth on Thursday sought to calm fears that the company's $54 billion acquisition by insurer Cigna would negatively impact St. Louis.
Moody's Investors Service has downgraded Cigna Corporation's long-term ratings, including its senior unsecured debt rating to Baa2 from Baa1, upon the closing of its acquisition of Express Scripts Holding Company (ESI, Baa2, Review Down). Total senior unsecured debt of approximately $41 billion includes $20 billion issued by subsidiary Halfmoon Parent, Inc. (now known as Cigna Corporation), legacy Cigna Corporation (now known as Cigna Holding Company) debt of approximately $5.3 billion and legacy ESI debt of approximately $12.8 billion.
Cigna Corp. completed its $54 billion acquisition of Express Scripts Holding Co., setting up a battle among giant health companies to try to cut health-care costs by managing both medical and drug benefits. The Cigna deal, which won an antitrust nod from the Justice Department without requiring divestitures, brings together a health insurer with a strong focus on employers with a major pharmacy-benefit manager. In an interview, Cigna Chief Executive David Cordani said an initial focus of the combined company will be on ensuring continued smooth business-as-usual operations, but it will begin rolling out new initiatives next year that seek to take advantage of the tie-up between medical and pharmacy oversight, including efforts focused on specialty pharmaceuticals and mental health.
Cigna Corp (CI.N) on Thursday closed its $54-billion (42.65 billion pounds) deal to buy Express Scripts Holding Co, creating one of the biggest providers of pharmacy benefits and insurance plans in the United States, a combination it says will help it improve healthcare coordination and cut costs. Cigna's deal puts it in direct competition with two other healthcare companies set up the same way - Aetna with CVS Health Corp (CVS.N) and UnitedHealth Group Inc (UNH.N) with Optum. Cigna's deal has already passed antitrust scrutiny.
Cigna closed on its acquisition of north St. Louis County-based Express Scripts Thursday after receiving final regulatory approval for the $54 billion deal on Wednesday.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting ESRX. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
Celanese Corp. shares rose in the extended session Wednesday after S&P Dow Jones Indices said the specialty chemical company would be joining the S&P 500 index . Celanese shares rose 4.8% after hours, following a 0.7% decline to close the regular session at $84.77. S&P said Celanese will trade on the index before the market opens on Monday, replacing Express Scripts Holding Co. which is being acquired by Cigna Corp.
NEW YORK , Dec. 19, 2018 /PRNewswire/ -- Celanese Corp. (NYSE: CE) will replace Express Scripts Holding Co. (NASD: ESRX) in the S&P 500 effective prior to the open of trading on Monday, December 24 . S&P ...
On Tuesday, regulators from New Jersey approved the deal, according to a Securities and Exchange (SEC) filing Wednesday. Both Cigna and Express Scripts said they expect to close the transaction Thursday now that all regulatory approvals have been received. Although the combined company will be headquartered in Bloomfield, Connecticut, the Express Scripts headquarters is expected to remain in St. Louis, with Tim Wentworth, president and CEO of the organization, leading the unit.
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / U.S. equities extended losses on Monday as investors await details from the Federal Reserve's final policy meeting of 2018 on Wednesday. The Dow Jones Industrial ...
Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.
Deepak Gulati‘s Argentiere Capital is a Zug, Switzerland-based hedge fund launched back in June 2013, with an additional office in Chicago. The fund is focused on offering its services to pooled investment vehicles and manages separate client-focused equity portfolios. It’s run by a team of former members of JP Morgan’s Global Equities Proprietary Trading Group […]
Only one state stands in the way of approving the $54 billion merger between Cigna and Express Scripts after government authorities in California and New York signed off on the deal Thursday. Both California's Department of Managed Health Care and New York's Department of Financial Services approved the deal and listed a set of conditions the companies agreed to. Conditions to the transaction in California Conditions to the transaction in New York Per the California approval, Cigna and Express Scripts agree to not increase premiums as a result of acquisition costs, and keep premium rate increases to a minimum.